News|Videos|November 20, 2026

48-Month Survival Analysis of the BENEFIT Trial, Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone for Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients

Xavier Leleu, MD, PhD, of Centre Hospitalier Universitaire de Poitiers in Poitiers, France, reviews the 48-month survival analysis of the phase 3 BENEFIT trial of isatuximab plus bortezomib, lenalidomide, and dexamethasone vs isatuximab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma, including 10-year projections of progression-free survival, as presented at the 23rd International Myeloma Society Annual Meeting.

Xavier Leleu, MD, PhD, of Centre Hospitalier Universitaire de Poitiers in Poitiers, France, presents the 48-month survival analysis of BENEFIT, a phase 3 study comparing isatuximab plus bortezomib, lenalidomide, and dexamethasone (Isa-VRd) with isatuximab plus lenalidomide and dexamethasone (Isa-Rd) in transplant-ineligible newly diagnosed multiple myeloma. Leleu notes that bortezomib was given only during induction, and that the first report showed a higher measurable residual disease negativity rate with Isa-VRd but no survival difference. At 48 months, the progression-free survival curves had separated in favor of Isa-VRd, although the difference was not statistically significant. In high-risk disease, more than 60% of patients given Isa-VRd were progression free vs about 40% given Isa-Rd. With 10-year modeling, 66% of patients given Isa-VRd and 34% given Isa-Rd are projected to be progression free. Leleu concludes that the 4-drug regimen should be considered the new standard of care for patients fit to receive it.


Related to this article